> ## Content Index
> Fetch the complete content index at: https://biopharmabrief.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# From Discovery to Scale: Georgia’s Ambitious Plan to Build a Life Sciences Powerhouse
- URL: https://biopharmabrief.com/from-discovery-to-scale-georgias-ambitious-plan-to-build-a-life-sciences-powerhouse/
- Published: 2026-11-19T14:30:00.000Z
- Updated: 2026-11-19T16:17:10.000Z
- Author: Jon Nugent

### *BioPharmaBrief's Innovation in the Southeast Series*

### Maria Thacker Goethe, President and CEO of Georgia Life Sciences, discusses the state’s evolution from a research-centered ecosystem into a growing biopharmaceutical manufacturing hub, the emerging companies attracting attention, and why Georgia’s next chapter will be defined by its ability to help innovation become commercial success. 

Georgia has long been recognized for its world-class research institutions, including Emory University, Georgia Tech and the University of Georgia, as well as the Centers for Disease Control and Prevention. Increasingly, however, the state is establishing itself as a destination for biotechnology entrepreneurship, biopharmaceutical manufacturing and life sciences commercialization. 

Major industry investments, a growing network of emerging biotechnology companies and an expanding manufacturing base are creating opportunities that extend well beyond the laboratory. Yet challenges remain. Access to growth capital, specialized manufacturing infrastructure and experienced leadership continue to influence whether young companies can remain in Georgia as they advance toward commercialization. 

For Maria Thacker Goethe, President and CEO of Georgia Life Sciences, addressing those challenges is central to the state’s next phase of development. Earlier this year, the organization introduced Pathways & Partnerships: A Roadmap for Georgia’s Life Sciences Sector, a 10-year strategy to strengthen the ecosystem and position Georgia as a regional center for scale-up and manufacturing. 

BioPharmaBrief spoke with Thacker Goethe about the industry’s evolution, the opportunities emerging across Georgia and what it will take to translate the state’s scientific strengths into long-term economic and commercial success. 

---

**BioPharmaBrief: You’ve been involved with Georgia’s life sciences industry for more than two decades. How has the ecosystem evolved during that time?** 

Maria Thacker Goethe: It’s been a remarkable evolution. When I first became involved with Georgia Life Sciences, the state was largely recognized for its academic research institutions, the CDC and a relatively small number of major industry employers, including Solvay and UCB. We had tremendous scientific expertise, but the ecosystem was fragmented. The connections between academic research, entrepreneurship and commercialization weren’t always well developed. Over the past two decades, Georgia has evolved from a primarily research-centered ecosystem into a much more diverse and sophisticated life sciences market. The industry now encompasses more manufacturing activity and a wider range of emerging companies. An encouraging development has been the increasing number of companies choosing to remain in Georgia rather than immediately relocating to established biotechnology centers after spinning out of our universities. Our academic institutions have become more engaged in commercialization and entrepreneurship. Emory, Georgia Tech and the University of Georgia have strengthened their efforts in developing the infrastructure and relationships needed to support emerging companies. Today, we have a much stronger network of incubators, accelerators and industry partnerships than we did 20 years ago. We’re certainly not finished building the ecosystem, but we’re in a fundamentally different position than when I started. 

**BioPharmaBrief: What do you consider Georgia’s most significant accomplishment during that period?** 

Maria Thacker Goethe: It’s the growing recognition that Georgia can support life sciences companies through multiple stages of development. For a long time, the conversation was largely about scientific discovery. We had world-class research, but the question was what happened to those technologies after they left the laboratory. Increasingly, we’re demonstrating that companies can conduct research in Georgia, develop their technologies here and ultimately establish manufacturing operations here. That’s a very important progression. We’re especially excited about the growth of biopharmaceutical and medical technology manufacturing because it creates the infrastructure and expertise that allow companies to remain in Georgia as they mature. Twenty years ago, we were largely trying to get people to recognize that Georgia had a life sciences industry. Today, we’re entering a much more important chapter: scaling. 

> “Increasingly, we’re demonstrating that companies can conduct research in Georgia, develop their technologies here and ultimately establish manufacturing operations here.” 

**BioPharmaBrief: Georgia Life Sciences recently introduced Pathways & Partnerships, a 10-year roadmap for the industry. What prompted that initiative, and what are its central priorities?** 

Maria Thacker Goethe: We’ve reached a point where the fundamental elements of a successful life sciences ecosystem are increasingly in place. We have the science. We have a growing infrastructure base. We have talent, although workforce development will always require continued attention. What we need now is a more coordinated strategy for connecting those strengths and addressing the gaps that continue to limit growth. That’s really the purpose of Pathways & Partnerships: A Roadmap for Georgia’s Life Sciences Sector. The roadmap lays out a vision of Georgia becoming a scale-up and manufacturing hub for the Southeast by 2035\. It emphasizes manufacturing infrastructure, workforce, access to capital and stronger partnerships across the ecosystem. Importantly, it isn’t simply a document we’ll put on a shelf. We’re building industry councils and bringing together leaders from across the ecosystem to guide implementation. Our councils concentrate on ecosystem development, medical devices and manufacturing, with workforce development emerging as a consistent priority. We’ll revisit our priorities and progress regularly as the industry evolves. 

**BioPharmaBrief: What are the biggest challenges facing Georgia biotechnology companies as they move from early-stage innovation toward commercialization and manufacturing?** 

Maria Thacker Goethe: The biggest challenge is the gap between proving that a technology works and building a business capable of producing it at commercial scale. Georgia has strengthened its support for early-stage innovation, with organizations such as the Georgia Research Alliance providing funding and resources for research and young companies. But that support does not always carry companies through the next stage. A company may have valuable intellectual property, an experienced scientific team and encouraging early data, but still lack the capital, infrastructure or manufacturing capabilities needed to move forward. That’s the missing middle. For many companies, it’s the stage where they either find the resources necessary to grow or begin looking outside Georgia for the support they need. That requires better access to scale-up financing, shared manufacturing infrastructure, specialized facilities and strategic partners. We want to create an environment where those companies have a realistic path from research and development through clinical development, commercialization and manufacturing without having to relocate. 

> “We want to create an environment where those companies have a realistic path from research and development through clinical development, commercialization and manufacturing without having to relocate.” 

**BioPharmaBrief: You mentioned shared manufacturing infrastructure and specialized facilities as part of the solution. What kinds of resources do emerging companies need most, and how is Georgia working to make them available?** 

Maria Thacker Goethe: We have strong research capabilities and a growing base of large-scale manufacturing operations, but there’s still a gap when it comes to the facilities emerging companies need as they begin to scale. We need more accessible GMP-ready pilot facilities and shared clean-room space. A young company may not have the resources to build its own manufacturing facility, but it still needs access to appropriate infrastructure to advance its technology. We’re exploring several approaches, including opportunities to use available capacity within existing facilities and the potential for public-private investment in shared infrastructure. Our manufacturing and medical device councils are already helping identify possibilities. The immediate priority is identifying practical ways to give startups access to facilities they could not afford independently. 

**BioPharmaBrief: Georgia has attracted substantial investments from established biopharmaceutical and medical technology companies. How do those investments benefit the broader ecosystem?** 

Maria Thacker Goethe: The impact goes well beyond the facilities themselves or the jobs they create. When major companies invest in Georgia, they bring specialized expertise, strengthen supplier networks and create demand for highly skilled workers. We’re seeing important investments from companies such as UCB, Meissner and Manus, along with continued expansion in medical technology and biopharmaceutical manufacturing. These companies need engineers, manufacturing specialists, regulatory professionals, quality experts and many other specialized employees. As that workforce grows, it creates a much deeper pool of expertise that emerging companies can potentially draw upon. Large-scale manufacturing investments also send an important signal: Georgia has the infrastructure, workforce and business environment to support sophisticated life sciences operations. But those benefits don’t automatically flow to smaller companies simply because a large manufacturer opens a facility nearby. We have to be intentional about building those connections. That’s why our roadmap emphasizes partnerships between established industry leaders and emerging companies. 

**BioPharmaBrief: What are some examples of the collaboration you’re beginning to see between established manufacturers and emerging companies?** 

Maria Thacker Goethe: Our medical device council has opened conversations between established manufacturers and younger companies about sharing capabilities and experience. Our manufacturing council is also bringing together experienced professionals who are willing to mentor emerging companies and share their expertise. For a young biotechnology company, access to someone who has already navigated manufacturing scale-up, regulatory requirements or quality systems can make a tremendous difference. The goal is to make these connections systematic rather than leaving them to chance. 

**BioPharmaBrief: Workforce development appears to be a major priority. How is Georgia preparing for the industry’s changing talent requirements?** 

Maria Thacker Goethe: Workforce development is the area where Georgia Life Sciences is doing some of its most intensive work. The scale of manufacturing investment we’re seeing creates tremendous demand for skilled employees. Companies are expanding facilities, building new operations and hiring people with specialized technical capabilities. At the same time, automation, artificial intelligence and advanced manufacturing technologies are reshaping the skills companies need. We have to think not only about preparing workers for today’s jobs, but also about the capabilities employers will require five or ten years from now. We’re working closely with industry partners, educational institutions and Georgia’s technical college system to strengthen that pipeline. One example of the scale of the opportunity is Meissner’s expansion in Athens, where the company is developing a substantial manufacturing campus. Investments of that magnitude require coordinated workforce planning. We want to ensure that the talent pipeline grows alongside the industry rather than becoming a constraint. 

**BioPharmaBrief: What role should state government play in supporting the next phase of Georgia’s life sciences growth?** 

Maria Thacker Goethe: Consistent state leadership is going to be essential. Georgia has been very successful in attracting major business investments, and we’ve benefited from a strong overall economic development environment. But life sciences has not always received the same degree of targeted attention as some other industries. We’ve seen neighboring states make deliberate investments in building their biotechnology ecosystems, and those investments are beginning to produce results. I believe Georgia needs to take a similarly deliberate approach. That could include investment in specialized infrastructure, support for commercialization and scale-up, workforce development and programs that help emerging companies attract capital. Life sciences is an industry with unique development requirements. Companies often face long timelines, significant regulatory complexity and substantial capital needs before they generate revenue. We have an opportunity to build on the scientific and industrial strengths already present in Georgia, but doing so will require coordinated leadership and long-term commitment. 

**BioPharmaBrief: Access to capital is another recurring theme. How can Georgia attract more attention from institutional investors and strategic partners?** 

Maria Thacker Goethe: That’s one of our biggest opportunities. Much of the biotechnology investment community remains concentrated in established markets on the East and West Coasts. I don’t expect that concentration to disappear, but I do believe we can do a much better job connecting Georgia companies with those investors and demonstrating why they should pay attention. We have innovative technologies and emerging companies that deserve greater visibility. We also have a significant opportunity to build stronger strategic partnerships between our homegrown innovators and established industry leaders already operating in Georgia. Johnson & Johnson has three facilities in the state, Boehringer Ingelheim's U.S. Animal Health business is headquartered here, and Boston Scientific's investment in Georgia-grown MiRus demonstrates the potential for these relationships to help emerging companies grow and scale. We should be more intentional about creating those connections. Sometimes investors become interested in a company but then encourage it to relocate to a more established biotechnology hub. Our executives often don’t want to leave Georgia. They have families here, they value the quality of life and they believe they can build successful businesses here. The question is how we help them access national and international capital without requiring them to move. Atlanta is a global business city, but we still have work to do to establish that same international connectivity within life sciences. We’re encouraged by growing attention from financial institutions and venture investors. For investors already visiting Atlanta, I’d encourage them to meet with local companies and see how much activity is taking place. 

**BioPharmaBrief: Are there emerging Georgia biotechnology companies that you believe deserve greater national attention?** 

Maria Thacker Goethe: Absolutely. One is Micron Biomedical, which originated from technology developed at Georgia Tech. Micron is advancing a dissolvable microarray platform designed for needle-free delivery of vaccines and therapeutics. It’s a compelling example of how academic research can evolve into a commercial enterprise. The company began in an incubator environment and opened a commercial-scale manufacturing facility in Alpharetta in May 2026\. It has attracted support from organizations including BARDA and the Gates Foundation. Micron demonstrates the pathway we want to encourage: research originating in Georgia, a company being built here and manufacturing capabilities established here as the technology advances. Andson Biotech is another example, also a Georgia Tech spinout. Andson is developing technology to simplify analytical workflows for advanced biologics, including applications relevant to cell and gene therapy development. Its DynaChip platform supports streamlined mass spectrometry analysis, and the company announced a $2 million NIH SBIR Phase II award in 2026\. I’ve enjoyed watching the company progress from its earliest stages through incubator programs and into its own facilities. It’s exactly the kind of emerging business that can benefit from Georgia’s growing expertise in advanced biomanufacturing. Another company I’d highlight is Moonlight Therapeutics, which is developing a skin-delivered allergen immunotherapy platform. Its investigational lead program, MOON101, targets peanut allergy and has advanced into early clinical development. Peanut allergies are a challenge many families understand personally, so it’s an example of biotechnology addressing a recognizable medical need. Saol Therapeutics, a rare disease company with operations in Roswell, has a pharmaceutical portfolio focused on areas including central nervous system disorders and orphan diseases. Together, these four companies illustrate the range of technologies and business models emerging from Georgia’s life sciences ecosystem. 

**BioPharmaBrief: Georgia’s life sciences industry extends beyond traditional human therapeutics. Are there interesting companies working in other areas?** 

Maria Thacker Goethe: That’s one of the things I find most exciting about Georgia. Our industry is incredibly diverse, and that diversity is a competitive advantage. Dalan Animal Health, based in Athens, developed the first USDA-approved vaccine for honeybees and is pursuing vaccine technology for shrimp. It’s a fascinating application of biotechnology to animal health and sustainable agriculture. Athens is increasingly interesting because of the University of Georgia and its connections to the broader Atlanta region. We’re also seeing interesting activity in industrial biotechnology. Manus operates a large-scale industrial biomanufacturing facility in Augusta and has research operations in the Boston area. The company has been expanding its manufacturing capabilities, including work involving materials used in essential medicines. These examples show how Georgia’s research and manufacturing capabilities support applications well beyond human medicines. 

**BioPharmaBrief: How is Georgia’s physical life sciences ecosystem evolving?** 

Maria Thacker Goethe: We’ve made real progress, although there’s certainly more work to do. One notable development has been Science Square in Atlanta, which represents a significant investment in purpose-built life sciences space. Facilities like that help create the physical environment where companies can grow, interact and build relationships. We’ve also learned that successful innovation ecosystems aren’t necessarily defined by having one enormous campus or biotechnology park. Georgia’s life sciences industry is geographically distributed, with important concentrations of activity in Atlanta, Athens, Augusta and other communities. That creates opportunities, but it also means we have to connect those locations more effectively. Portal Innovations’ departure from its Atlanta incubator operation has been disappointing because it provided valuable space and helped bring emerging companies together. But I don’t view that as a reflection of weak demand in Georgia. The operation had been attracting companies, and most of the businesses affected have remained in the state. The broader momentum continues. We need a range of infrastructure solutions that reflect the needs of companies at different stages, including incubator space, specialized laboratories, shared facilities and manufacturing capabilities. 

**BioPharmaBrief: Looking ahead five years, what would success look like for Georgia’s life sciences industry?** 

Maria Thacker Goethe: I would hope we’re seeing measurable progress toward our goal of making Georgia a leading scale-up and manufacturing hub for the Southeast. That means more companies successfully moving from research and development into clinical development, commercialization and manufacturing, and choosing to remain in Georgia as they grow. It means stronger infrastructure and capital networks to help companies navigate the difficult transition between early-stage innovation and commercial scale. It also means a workforce pipeline capable of responding to the industry’s changing needs. But for investors and business development professionals, the most compelling measures will be commercial outcomes. I’d like to see a meaningful increase in investment activity, licensing agreements, strategic partnerships and successful exits involving Georgia companies. Those are milestones that demonstrate an ecosystem is creating lasting value. I also hope we’re seeing more dedicated public investment in life sciences. Ultimately, I want us to look back five years from now and recognize that Georgia has become a place where companies don’t simply get started. They have every reason to stay, scale and succeed. 

> “Georgia has become a place where companies don’t simply get started. They have every reason to stay, scale and succeed.” 

**BioPharmaBrief: Finally, what would you most like investors and biotechnology executives outside Georgia to understand about the opportunities emerging in the state?** 

Maria Thacker Goethe: Georgia remains an under-the-radar opportunity. There’s more life sciences innovation happening here than many people outside the state realize. We have emerging companies, world-class research institutions and a growing manufacturing footprint, and that range gives us a strong foundation for continued growth. Through our roadmap, we’re bringing the community together to tell that story nationally as one ecosystem, not just as individual institutions and companies. We’re also building stronger connections to the national and international investment community, because we want more investors and strategic partners to see the commercial potential of the work happening here. For anyone looking at emerging biotechnology opportunities in the Southeast, I would encourage them to take a closer look at Georgia. 

---

*This interview has been edited for clarity, length and readability.*